{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:05:13Z","timestamp":1773234313207,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00192-016-3199-x","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T12:11:39Z","timestamp":1479125499000},"page":"777-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Changes in intraocular pressure and tear secretion in patients given 5\u00a0mg solifenacin for the treatment of overactive bladder"],"prefix":"10.1007","volume":"28","author":[{"given":"Ali Riza","family":"Turkoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan Parmak","family":"Yener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soner","family":"Coban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Guzelsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Demirbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"issue":"3","key":"3199_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/0971-9261.154662","volume":"20","author":"D Jain","year":"2015","unstructured":"Jain D, Dhua A, Ravisankar V, Chellam L, Joshi MJ. Acute angle closure glaucoma after hypospadias surgery: a vision-threatening complication of oxybutynin. J Indian Assoc Pediatr Surg. 2015;20(3):161\u20132. doi: 10.4103\/0971-9261.154662 .","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"3199_CR2","first-page":"266","volume":"14","author":"Y Homma","year":"2003","unstructured":"Homma Y, Kakizaki H, Gotoh M, et al. Epidemiologic survey on urination. J Jpn Neurogenic Bladder Soc. 2003;14:266\u201377.","journal-title":"J Jpn Neurogenic Bladder Soc"},{"issue":"1","key":"3199_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","volume":"43","author":"K-E Andersson","year":"2003","unstructured":"Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor\u2015which is the main mechanism of action? Eur Urol. 2003;43(1):1\u20135.","journal-title":"Eur Urol"},{"key":"3199_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.bjp.0706147","volume":"144","author":"KJ Mansfield","year":"2005","unstructured":"Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144:1089\u201399.","journal-title":"Br J Pharmacol"},{"key":"3199_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000209255","volume":"83","author":"D Giglio","year":"2009","unstructured":"Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83:259\u201369.","journal-title":"Pharmacology"},{"key":"3199_CR6","first-page":"28","volume":"4","author":"HH Lai","year":"2002","unstructured":"Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4:28\u201337.","journal-title":"Rev Urol"},{"key":"3199_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1177\/0091270004267592","volume":"44","author":"RA Smulders","year":"2004","unstructured":"Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023\u201333.","journal-title":"J Clin Pharmacol"},{"key":"3199_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"KE Andersson","year":"2004","unstructured":"Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46\u201353.","journal-title":"Lancet Neurol"},{"key":"3199_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.clinthera.2006.11.010","volume":"28","author":"AD Garely","year":"2006","unstructured":"Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28:1935\u201346.","journal-title":"Clin Ther"},{"key":"3199_CR10","first-page":"1","volume":"4","author":"MA Sekeroglu","year":"2015","unstructured":"Sekeroglu MA, Hekimoglu E, Tasci Y, Dolen I, Arslan U. Ocular surface changes following oral anticholinergic use for overactive bladder. Cutan Ocul Toxicol. 2015;4:1\u20134.","journal-title":"Cutan Ocul Toxicol"},{"issue":"5","key":"3199_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P Abrams","year":"2007","unstructured":"Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987\u20131006.","journal-title":"BJU Int"},{"issue":"1","key":"3199_CR12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(17)41482-0","volume":"140","author":"JG Ouslander","year":"1988","unstructured":"Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong CL. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol. 1988;140(1):47\u201350.","journal-title":"J Urol"},{"issue":"5","key":"3199_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2125.2005.02356.x","volume":"59","author":"R Altan-Yaycioglu","year":"2005","unstructured":"Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, Guyel S, Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol. 2005;59(5):588\u201392.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3199_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00192-014-2396-8","volume":"25","author":"MA Sekeroglu","year":"2014","unstructured":"Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014;25(11):1479\u201382.","journal-title":"Int Urogynecol J"},{"issue":"4","key":"3199_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1046\/j.1464-410x.1998.00403.x","volume":"81","author":"VC Sung","year":"1998","unstructured":"Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol. 1998;81(4):634\u20135.","journal-title":"Br J Urol"},{"issue":"11","key":"3199_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2165\/00002018-200326110-00002","volume":"26","author":"RC Tripathi","year":"2003","unstructured":"Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf. 2003;26(11):749\u201367.","journal-title":"Drug Saf"},{"issue":"7","key":"3199_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1442-2042.2007.01791.x","volume":"14","author":"K Kato","year":"2007","unstructured":"Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595\u20137.","journal-title":"Int J Urol"},{"key":"3199_CR18","first-page":"151","volume":"39","author":"S Bacman","year":"1998","unstructured":"Bacman S, Perez Leiros C, Sterin-Borda L\u015e, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptor in patients with primary Sj\u00f6gren\u2019s syndrome. Invest Ophthalmol Vis Sci. 1998;39:151\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3199_CR19","series-title":"Basic and clinical science course section 8","first-page":"53","volume-title":"External disease and cornea","author":"American Academy of Ophthalmology","year":"2005","unstructured":"American Academy of Ophthalmology (2005). External disease and cornea. Basic and clinical science course section 8. San Francisco: AAO. p. 53\u201361."}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-016-3199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00192-016-3199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-016-3199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T15:12:33Z","timestamp":1568560353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00192-016-3199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3199"],"URL":"https:\/\/doi.org\/10.1007\/s00192-016-3199-x","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]}}}